Literature DB >> 10378688

The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation.

M D Cole1, S B McMahon.   

Abstract

Mutations which disrupt the regulation or expression level of the c-myc gene are among the most common found in human and animal cancers (reviewed in ref. Cole, 1986; Henriksson and Luscher, 1996; Marcu et al., 1992). Ectopic expression studies define numerous biological activities of the c-myc gene, including transformation, immortalization, blockage of cell differentiation and induction of apoptosis (Askew et al., 1991; Cole, 1986; Evan and Littlewood, 1993; Freytag et al., 1990; Henriksson and Luscher, 1996; Marcu et al., 1992). Furthermore, c-myc is required for efficient progression through the cell cycle (Goruppi et al., 1994; Prochownik et al., 1988; Yokoyama and Imamoto, 1987), although recent studies indicate that it is not absolutely essential (Mateyak et al., 1997). This fascinating array of biological activities makes the c-myc gene one of the most intriguing oncogenes and presents the challenging question of how a single gene can manifest so many different effects. The c-Myc protein exhibits sequence-specific DNA binding when dimerized with its partner Max, and DNA binding is mediated through the basic region, which recognizes the core sequence CACGTG (Berberich et al., 1992; Blackwell et al., 1993; Blackwood and Eisenman, 1991; Prendergast and Ziff, 1991; Prendergast et al., 1991), but exhibits somewhat higher affinity for the more extended sequence ACCACGTGGT (Berberich et al., 1992; Blackwell et al., 1993; Halazonetis and Kandil, 1991). There are three closely related Myc family proteins (c-Myc, N-Myc and L-Myc), each with documented oncogenic potential (Birrer et al., 1988; Schwab et al., 1985; Yancopoulos et al., 1985) and similar DNA binding properties (Mukherjee et al., 1992). For simplicity, we will use the term Myc to refer to all three proteins, but delineate any distinct activities where they apply. The goal of this review is to discuss Myc as a transcriptional activator and critically evaluate the evidence for the transactivation of specific target genes as direct downstream effectors. Since excellent comprehensive reviews on Myc have been published recently (Facchini and Penn, 1998; Henriksson and Luscher, 1996), we will focus on the latest observations that offer mechanistic insight into transactivation and oncogenic transformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378688     DOI: 10.1038/sj.onc.1202748

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  106 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals.

Authors:  D W Chang; G F Claassen; S R Hann; M D Cole
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  S-phase-specific expression of the Mad3 gene in proliferating and differentiating cells.

Authors:  E J Fox; S C Wright
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

4.  Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.

Authors:  D Xu; N Popov; M Hou; Q Wang; M Björkholm; A Gruber; A R Menkel; M Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

5.  In silico identification of transcriptional regulators associated with c-Myc.

Authors:  Ran Elkon; Karen I Zeller; Chaim Linhart; Chi V Dang; Ron Shamir; Yosef Shiloh
Journal:  Nucleic Acids Res       Date:  2004-09-23       Impact factor: 16.971

Review 6.  Gfi/Pag-3/senseless zinc finger proteins: a unifying theme?

Authors:  Hamed Jafar-Nejad; Hugo J Bellen
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  The impact of C-MYC gene expression on gastric cancer cell.

Authors:  Lin Zhang; Yanhong Hou; Hassan Ashktorab; Liucun Gao; Yanjie Xu; Kai Wu; Junshan Zhai; Lei Zhang
Journal:  Mol Cell Biochem       Date:  2010-08-25       Impact factor: 3.396

8.  Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.

Authors:  Shala Dezfouli; Antony Bakke; Jie Huang; Anthony Wynshaw-Boris; Peter J Hurlin
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

9.  c-MYC apoptotic function is mediated by NRF-1 target genes.

Authors:  Fionnuala Morrish; Christopher Giedt; David Hockenbery
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

Review 10.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.